Serial No. 756,025

#6. (E)-(1R, 1'R)-2, 2'-[4-Octenedicylbis(oxytri-methylene)]bis[1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-methyl-1@(3, 4, 5-trimethoxybenzyl)isoquinolinium] cation in association with a pharmaceutically acceptable anion.

47. (E)-(1R, 1'R)-2, 2'-[4-Octenedicylbis(oxytrimethylene)]bis[1, 2, 4, 3-tetrahydro-6, 7-dimethoxy-2-methyl-1=
(3, 4, 5-trimethoxybenzyl)isoquinolinium] dichloride

48. (E)-(1R, 1'R, 2R, 2'R)-2, 2'-[4-Octenedicylbis(oxytrimethylene)]bis[1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-methyl-1@)
(3, 4, 5-trimethoxybenzyl) isoquinolinium] cation in association with a pharmaceutically acceptable anion.

 $49. \quad (E) = (1R, \frac{1}{R}, 2R, \frac{2}{R}) - 2, 2! - [4-Octenedicylbis (oxytrimethylene)] bis[1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-methyl-1+ (3, 4, 5-trimethoxybenzyl) isoquinolinium] dichloride$ 

(E)-(1R, 1'R, 2R, 2'S)-2, 2'-[4-Octenedicylbis(oxytri|-(1, 1)|
methylene)]bis[1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-methyl1-(3, 4, 5-trimethoxybenzyl)isoquinolinium] dichloride

52. (E)-(1R, 1, R, 2S, 2, S)-2, 2, -[4-Octenedicylbis(oxytrimethylene)]bis[1, 2, 3, 4-tetrahydro-6, 7-dimethoxy-2-methyl-1 $\in$  (3, 4, 5-trimethoxybenzyl)isoquinolinium] cation in association



Serial No. 756,025

with a pharmaceutically acceptable anion.

methylene)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1 $\in$  (3,4,5-trimethoxybenzyl)isoquinolinium] dichloride

54. A method for producing muscle relaxation in a mammal which comprises parenterally administering to a mammal an effective muscle relaxant amount of the compound of claim 42, 44 or 45.

55. A sterile pharmaceutical composition comprising one or more of the compounds of claims 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 or 53 in an effective muscle relaxant amount and a pharmaceutically acceptable solvent therefor.

56. A method for producing muscle relaxation in a mammal which comprises parenterally administering to a mammal an effective muscle relaxant amount of one or more of the compounds of claims 50, 51, 52 or 53:

## REMARKS

Applicants have cancelled claims 19 to 41 and inserted re written claims 42 to 56 to reduce the claims to 15 in number and at the same time adequately cover the invention.

Claims 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 and 53 track Examples 1, 2, 3 and 4 and claim compounds disclosed as C (Example 1), D (Example 2), G (Example 3), H, I, J (Example 4).

For the claims 42, 44, 46, 48, 50 and 52 the anion is